Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

230 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-18

Study Completion Date

2025-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Esophageal and esophagogastric junction cancer is still one of the main health care issue and esophagectomy with lymph node dissection is the only chance to be cure.

However, esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24% and a mortality rate of 2% to 5.6%, respectively There is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Postoperative Morbidity and Mortality After Gastric Cancer Surgery

NCT06277908

Gastric Cancer Siewert Type III Adenocarcinoma of Esophagogastric Junction Stomach Cancer

NOT_YET_RECRUITING

Outcomes After Esophageal Cancer Surgery

NCT01927016

Esophageal Neoplasm Esophageal Disease

COMPLETED

Postoperative Morbidity and Mortality After Gastrectomy for Gastric Cancer: Prospective Cohort Study

NCT01919242

Patients Who Underwent Gastrectomy With Lymph Node Dissection for Gastric Cancer

UNKNOWN

Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases

NCT02642185

Neoplasm Metastasis

COMPLETED

Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors

NCT04764409

Hepatic Cancer Metastatic Cancer Chemotherapy Effect

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Esophageal and esophago-gastric junction cancer is the seventh most common malignancy and the sixth leading cause of cancer-related mortality worldwide.

Surgery remains the primary treatment for esophageal cancer and is one of the most technically challenging interventions in oncological surgery. In addition, esophagectomy is associated with high risks of postoperative complications, with rates varying from clinic to clinic. Esophagectomy for esophageal cancer is a complex procedure which carries high risk of morbidity rate of 24% and a mortality rate of 2% to 5.6%, respectively.

The problem with the available studies of the course of the postoperative period is the significant heterogeneity of research methods, which does not allow us to obtain a true picture of the results of surgical treatment of the esophagus and esophagogastric junction cancer in the Russian Federation.

To improve the quality of further studies and recommendations on standardization of surgical treatment of esophageal and esophagogastric junction cancer and its morbidity, there is a need to study the differences of 90-day postoperative morbidity and mortality in different clinics and centers of the Russian Federation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer Oesophageal Cancer Siewert Type I Adenocarcinoma of Esophagogastric Junction Siewert Type III Adenocarcinoma of Esophagogastric Junction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with morbidity and mortality

Patients who suffered from any type of morbidity after surgery

Elective Surgery for gastric cancer

Intervention Type PROCEDURE

Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach

Patients without morbidity and mortality

Patients who did not suffer from any type of morbidity after surgery

Elective Surgery for gastric cancer

Intervention Type PROCEDURE

Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Elective Surgery for gastric cancer

Resection of the esophagus and the gastroesophageal junction via open, laparoscopic or robotic approach

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Esophageal or Esophagogastric Junction Cancer

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All consecutive patients with clinically documented primary Esophageal or Esophagogastric Junction malignancy (including Siewert I and II) undergoing elective surgery with curative intent - via open, laparoscopic or robotic approach between 18th March 2024 and 18th September 2024

Exclusion Criteria

* Patients with clinical evidence of metastatic disease, including positive peritoneal cytology on a previous staging laparoscopy, or those with known synchronous other cancers.
* Esophagogastric Junction Siewert III malignancy
* Patients submitted to Emergency surgery or surgery without curative intent
* Patients undergoing any other surgery in addition to the curative surgery for primary Esophageal or Esophagogastric Junction malignancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No